Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism?

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 2, 2012, Pages 122-128

  Suchankova, Petra ^a   Klang, Jonas ^a   Cavanna, Carin ^a   Holm, Göran ^a   Nilsson, Staffan ^b   Jönsson, Erik G ^c   Ekman, Agneta ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLYCINE; SERINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC CODE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; PERSONALITY DISORDER; POPULATION; PSYCHOSIS; SCHIZOPHRENIA;

EID: 84857539388     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110024     Document Type: Article

References (47)

1. Tsoporis JN, Izhar S, Leong-Poi H, et al. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptormediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010; 106:93-101.
2. Daborg J, von Otter M, Sjolander A, et al. Association of the RAGE G82S polymorphism with Alzheimer's disease. J Neural Transm 2010; 117:861-7.
3. Schmidt AM, Yan SD, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111.
4. Rothermundt M, Missler U, Arolt V, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correl ated with negative symptomatology. Mol Psychiatry 2001;6:445-9.
5. Steiner J, Bielau H, Bernstein HG, et al. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006;77:1284-7.
6. Steiner J, Walter M, Wunderlich MT, et al. A new pathophysio logical aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009;65:1107-10.
7. Liu L, Li Y, Van Eldik LJ, et al. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem 2005;92:546-53.
8. Ponath G, Schettler C, Kaestner F, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007;184:214-22.
9. Zhang FL, Gao HQ, Shen L. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells. J Cardiovasc Pharmacol 2007;50:434-40.
10. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006;13:1971-8.
11. Gaens KH, Ferreira I, van der Kallen CJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009;94:5174-80.
12. Caspi A, Roberts BW, Shiner RL. Personality development: stability and change. Annu Rev Psychol 2005;56:453-84.
13. De Pauw SS, Mervielde I. Temperament, personality and developmental psychopathology: a review based on the conceptual dimensions underlying childhood traits. Child Psychiatry Hum Dev 2010; 41:313-29.
14. Suchankova P, Baghaei F, Rosmond R, et al. Genetic variability within the S100B gene influences the personality trait self-directedness. Psychoneuroendocrinology 2011;36:919-23.
15. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-8.
16. Baghaei F, Rosmond R, Landen M, et al. Phenotypic and genotypic characteristics of women in relation to personality traits. Int J Behav Med 2003;10:365-78.
17. Rosmond R, Dallman MF, Björntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998;83:1853-9.
18. Schalling D, Asberg M, Edman G, et al. Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity. Acta Psychiatr Scand 1987;76:172-82.
19. Gustavsson JP, Pedersen NL, Asberg M, et al. Origins of individual differences in anxiety proneness: a twin/adoption study of the anxiety-related scales from the Karolinska Scales of Personality (KSP). Acta Psychiatr Scand 1996;93:460-9.
20. Laakso A, Wallius E, Kajander J, et al. Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am J Psychiatry 2003;160:904-10.
21. Gustavsson JP, Weinryb RM, Goransson S, et al. Stability and predictive ability of personality traits across 9 years. Pers Individ Dif 1997;22:783-91.
22. Westberg L, Melke J, Landen M, et al. Association between a dinucleotide repeat polymorphism of the estrogen receptor alpha gene and personality traits in women. Mol Psychiatry 2003;8:118-22.
23. Jönsson EG, Sillen A, Vares M, et al. Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and metaanalysis. Am J Med Genet B Neuropsychiatr Genet 2003;119B:28-34.
24. Jönsson E, Lannfelt L, Sokoloff P, et al. Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr Scand 1993;87:345-9.
25. Fratiglioni L, Viitanen M, Backman L, et al. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 1992;11(Suppl 1):29-36.
26. Farde L, Gustavsson JP, Jönsson E. D2 dopamine receptors and personality traits. Nature 1997;385:590.
27. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789-94.
28. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psych osis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
29. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
30. Li K, Dai D, Zhao B, et al. Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm 2010;117: 97-104.
31. Kondel TK, Hirsch SR, Laws KR. Name relearning in elderly patients with schizophrenia: episodic and temporary, not semantic and permanent. Cogn Neuropsychiatry 2006;11:1-12.
32. Glantz LA, Gilmore JH, Lieberman JA, et al. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006;81:47-63.
33. Müller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders - relation to drug treatment. Dialogues Clin Neurosci 2009;11:319-32.
34. Wiesmann M, Wandinger KP, Missler U, et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 1999;45:1508-11.
35. Lara DR, Gama CS, Belmonte-de-Abreu P, et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001;35:11-4.
36. Coccaro EF. Association of C-reactive protein elevation with trait aggression and hostility in personality disordered subjects: a pilot study. J Psychiatr Res 2006;40:460-5.
37. Suchankova P, Henningsson S, Baghaei F, et al. Genetic variability within the innate immune system influences personality traits in women. Genes Brain Behav 2009;8:212-7.
38. Centonze D, Muzio L, Rossi S, et al. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 2010;17:1083-91.
39. Linthorst ACE, Reul JMHM. Brain neurotransmission during peripheral inflammationa. Ann N Y Acad Sci 1998;840:139-52.
40. Stellwagen D, Beattie EC, Seo JY, et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005;25:3219-28.
41. Donato R, Sorci G, Riuzzi F, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009;1793: 1008-22.
42. Gardini S, Cloninger CR, Venneri A. Individual differences in personality traits reflect structural variance in specific brain regions. Brain Res Bull 2009;79:265-70.
43. Mitchell KJ. The genetics of neurodevelopmental disease. Curr Opin Neurobiol 2011;21:197-203.
44. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 2010;123:234-43.
45. Arai M, Yuzawa H, Nohara I, et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 2010;67:589-97.
46. Alexiou P, Chatzopoulou M, Pegklidou K, et al. RAGE: a multiligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010;17:2232-52.
47. Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci 2008;62:23-31.